関連する実験動画
Updated: May 11, 2026

06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
治療不耐性自己免疫結合組織疾患に対する二固有のT細胞エンゲージャー
Christina Düsing1,2,3, Andrea-Hermina Györfi1,2,3, Ayla Nadja Stütz1,2
1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany.
Nature medicine
|February 19, 2026
まとめ
ブリナトゥモマブとテクリスタマブは,重度の抗合成酵素症候群 (ASyS) と全身性硬化症 (SSc) の救済療法として有望であることが示されています. これらのT細胞エンゲージャー (TCE) は,治療抵抗性の患者で症状を改善し,自己抗体を減少させた.
科学分野:
- 免疫学 免疫学とは
- レウマトロジーの病理学
- 腫瘍学 腫瘍学
背景:
- 抗合成酵素症候群 (ASyS) と全身性硬化症 (SSc) は,重要な満たされていない医療ニーズを持つ自己免疫疾患です.
- 治療に抵抗する症例は,新たな治療戦略を必要とし,課題を提起します.
研究 の 目的:
- 治療抵抗性ASySおよびSScに対する同情的な使用療法としてのブリナトゥモマブおよびテクリスタマブの有効性と安全性を評価する.
- これらのT細胞エンゲージャー (TCE) が疾患マーカー,臨床結果,有害事象に与える影響を評価する.
主な方法:
- 治療抵抗性ASySの患者5人は,ブリナトゥモマブ (CD19×CD3 TCE) を受けました.
- 治療抵抗性SScを有する5人の患者はテクリスタマブ (BCMA×CD3 TCE) を受けた.
- リトゥキシマブ (RTX) による維持療法は,B細胞の再差異化を抑制するために使用されました.
主要な成果:
- ブライナトゥモマブは,ASyS患者における筋炎を改善し,間位肺疾患 (ILD) を安定させ,標的細胞と自己抗体を減少させた.
- Teclistamabは,皮膚線維症を改善し,ILDを安定させ,SSc患者の摩擦摩擦を解決しました.
- RTXの維持により,RTXに反応しない患者でも,長期間の疾患制御が達成されました. 副作用には,サイトカイン放出症候群 (CRS) と呼吸器感染症が含まれていました.
結論:
- ブリナトゥモマブおよびテクリスタマブは,耐火性ASySおよびSScに対する救助療法としての可能性を実証しています.
- これらのTCEは,臨床的,血清学的,および組織学的改善を誘発することができます.
- これらの複雑な自己免疫疾患の管理におけるその役割を確立するために,さらなる調査が必要である.
さらに関連する動画
関連する概念動画
Cell-mediated Immune Responses
Overview
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

